Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma

Simple Summary Hepatocellular carcinoma (HCC), a type of liver cancer, remains a treatment challenge due to late detection and resistance to currently approved drugs. It takes 15–20 years for a single new drug to become FDA approved. The purpose of this study was to expedite identification of novel drugs against drug-resistant HCC. For this, we matched gene expression alterations in resistant HCC with gene expression changes caused by treatment of cancer cells with drugs already FDA approved for other diseases to find the drug that can reverse the resistance-related changes. Among the identified drugs, we validated the growth inhibitory effect of two drugs, identified their mechanism in HCC and, thus, provided proof of concept evidence for validity of this drug repurposing approach with potential for use in personalized medicine. Abstract Objective: Hepatocellular carcinoma (HCC) is frequently diagnosed in patients with late-stage disease who are ineligible for curative surgical therapies. The majority of patients become resistant to sorafenib, the only approved first-line therapy for advanced cancer, underscoring the need for newer, more effective drugs. The purpose of this study is to expedite identification of novel drugs against sorafenib resistant (SR)-HCC. Methods: We employed a transcriptomics-based drug repurposing method termed connectivity mapping using gene signatures from in vitro-derived SR Huh7 HCC cells. For proof of concept validation, we focused on drugs that were FDA-approved or under clinical investigation and prioritized two anti-neoplastic agents (dasatinib and fostamatinib) with targets associated with HCC. We also prospectively validated predicted gene expression changes in drug-treated SR Huh7 cells as well as identified and validated the targets of Fostamatinib in HCC. Results: Dasatinib specifically reduced the viability of SR-HCC cells that correlated with up-regulated activity of SRC family kinases, its targets, in our SR-HCC model. However, fostamatinib was able to inhibit both parental and SR HCC cells in vitro and in xenograft models. Ingenuity pathway analysis of fostamatinib gene expression signature from LINCS predicted JAK/STAT, PI3K/AKT, ERK/MAPK pathways as potential targets of fostamatinib that were validated by Western blot analysis. Fostamatinib treatment reversed the expression of genes that were deregulated in SR HCC. Conclusion: We provide proof of concept evidence for the validity of this drug repurposing approach for SR-HCC with implications for personalized medicine.

[1]  R. Finn,et al.  Molecular therapies for HCC: Looking outside the box. , 2020, Journal of hepatology.

[2]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Paula Esther Moraga-Serrano.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016:A Systematic Analysis for the Global Burden of Disease Study , 2018 .

[4]  M. Kudo,et al.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.

[5]  Mohammad Hossein Khosravi,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 , 2018, JAMA oncology.

[6]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[7]  Fuhai Li,et al.  MD-Miner: a network-based approach for personalized drug repositioning , 2017, BMC Systems Biology.

[8]  J. Goeman,et al.  Minimally adaptive BH: A tiny but uniform improvement of the procedure of Benjamini and Hochberg , 2017, Biometrical journal. Biometrische Zeitschrift.

[9]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[10]  Atul J Butte,et al.  Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. , 2017, Gastroenterology.

[11]  Tong Wu,et al.  TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells , 2017, Molecular carcinogenesis.

[12]  K. Ghoshal,et al.  Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production. , 2017, Gene expression.

[13]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[14]  Steven J Schrodi,et al.  The Use of Multiplicity Corrections, Order Statistics and Generalized Family-Wise Statistics with Application to Genome-Wide Studies , 2016, PloS one.

[15]  S. Dooley,et al.  TGF-β1 and TGF-β2 abundance in liver diseases of mice and men , 2016, Oncotarget.

[16]  Shuqun Cheng,et al.  ICAM-1–Related Noncoding RNA in Cancer Stem Cells Maintains ICAM-1 Expression in Hepatocellular Carcinoma , 2015, Clinical Cancer Research.

[17]  J. Llovet,et al.  Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma , 2015, Gut.

[18]  M. Morimoto,et al.  Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma , 2015, BMC Research Notes.

[19]  Y. Moreau,et al.  Beegle: from literature mining to disease-gene discovery , 2015, Nucleic acids research.

[20]  Wen Li,et al.  MicroRNA-129-5p inhibits hepatocellular carcinoma cell metastasis and invasion via targeting ETS1. , 2015, Biochemical and biophysical research communications.

[21]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[22]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[23]  Qichao Xie,et al.  Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study. , 2015, International journal of clinical and experimental medicine.

[24]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[25]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[26]  R. Geahlen,et al.  Getting Syk: spleen tyrosine kinase as a therapeutic target. , 2014, Trends in pharmacological sciences.

[27]  Bertil Schmidt,et al.  CellMinerHCC: a microarray‐based expression database for hepatocellular carcinoma cell lines , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[28]  Tsung-Han Hsieh,et al.  Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC , 2013, BMC Genomics.

[29]  A. Chang,et al.  Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells , 2013, BMC Cancer.

[30]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[31]  Jing-jing Hu,et al.  Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. , 2013, Gastroenterology.

[32]  J. Dering,et al.  Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro , 2013, Hepatology.

[33]  Ying-jian Liang,et al.  Hypoxia‐mediated sorafenib resistance can be overcome by EF24 through Von Hippel‐Lindau tumor suppressor‐dependent HIF‐1α inhibition in hepatocellular carcinoma , 2013, Hepatology.

[34]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[35]  J. Friedberg,et al.  Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia , 2013, Leukemia.

[36]  Frederik Nevens,et al.  Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. , 2013, Cancer letters.

[37]  C. Porta,et al.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.

[38]  Stephanie Roessler,et al.  Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. , 2012, Gastroenterology.

[39]  J. Llovet,et al.  Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib , 2012, Clinical Cancer Research.

[40]  D. Payan,et al.  Discovery and development of spleen tyrosine kinase (SYK) inhibitors. , 2012, Journal of medicinal chemistry.

[41]  Cheng-Yan Kao,et al.  Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma , 2011, PloS one.

[42]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[43]  C. Pirker,et al.  A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression , 2011, Molecular Cancer Therapeutics.

[44]  Yujin Hoshida,et al.  Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment , 2010, PloS one.

[45]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[46]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[47]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[48]  I. Gelman,et al.  Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro , 2009, Digestive Diseases and Sciences.

[49]  S. Ogane,et al.  Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma , 2009, International journal of cancer.

[50]  Jing Chen,et al.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..

[51]  Eun Sung Park,et al.  Identification of potential driver genes in human liver carcinoma by genomewide screening. , 2009, Cancer research.

[52]  P. Abbe,et al.  Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. , 2009, Cancer research.

[53]  Mathieu Bastian,et al.  Gephi: An Open Source Software for Exploring and Manipulating Networks , 2009, ICWSM.

[54]  R. Fisher,et al.  Genes Involved in Viral Carcinogenesis and Tumor Initiation in Hepatitis C Virus-Induced Hepatocellular Carcinoma , 2009, Molecular medicine.

[55]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[56]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[57]  Li Wang,et al.  Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma , 2006, Clinical Cancer Research.

[58]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[59]  P. Coopman,et al.  The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. , 2006, Cancer letters.

[60]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[61]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[63]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[64]  A. Sahin,et al.  Hypermethylation leads to silencing of the SYK gene in human breast cancer. , 2001, Cancer research.

[65]  M. Monden,et al.  Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. , 2001, Journal of hepatology.

[66]  P. Rosenthal,et al.  American Association for the Study of Liver Diseases , 1993, IDrugs : the investigational drugs journal.

[67]  S. Fernandez,et al.  Fully Moderated T-statistic for Small Sample Size Gene Expression Arrays , 2011, Statistical applications in genetics and molecular biology.